risks of glp 1 INFOGRAPHIC: The Hidden GLP-1 Weight Loss Medications Long-Term Risks of GLP-1 Drugs:

Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA)

Brand-name versions cost upto$1,000$1,300 monthly

Shift could reflect a changing demand away from oncology toward addressing metabolic disorders

GLP-1 in addiction medicine: GLP-1 acts on pancreas, gut, kidney, heart and thyroid receptors to activate reward/stress hubs (VTA, NAc, ARC, PFC, hypothalamus)

The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)